Drugs that remove or quiet senescent cells could reduce inflammatory aging signals, but benefits depend heavily on context.

Sources: [1]Reference 1Human senolytic pilotHickson et al., EBioMedicine, 2019Preliminary human dasatinib plus quercetin study in diabetic kidney disease.[2]Reference 2Senolytic clinical follow-upSenolytic combination clinical literature, 2024Use for inflammation, tissue specificity, and clinical endpoint caution.

Evidence standingEarly human
Key facts
Portal
Longevity Science
Stage
Early human studies
Evidence
Early human
Reversible
Context dependent
Reviewed
May 2026
Read time
6 min
Contents

Page status

Needs larger randomized human studies · Needs tissue-specific benefit-risk framing

Key takeaways

  • Senescent cells can be harmful, protective, or useful depending on timing and tissue.
  • Intermittent dosing is attractive because the target accumulates over time.
  • Frailty, fibrosis, metabolic disease, and immune aging remain major areas to watch.

Mechanism

Senolytics try to selectively kill senescent cells. Senomorphics try to reduce the inflammatory secretions those cells produce without necessarily removing them.

The central design problem is selectivity. A therapy that broadly damages stressed but useful cells can undermine repair, wound healing, or immune function.

Practical interpretation

Aging biology rarely maps to a single villain. Senescence is part of cancer suppression and tissue repair, so timing matters as much as the molecular target.

The best evidence will come from endpoints tied to function: mobility, organ performance, fibrosis, immune response, and recovery after stress.

Open questions

  • In which contexts does clearing senescent cells help versus harm?
  • What are the right dosing schedules?

Watchlist

Signals that would move this entry along the evidence scale.

Intermittent protocolsCombination therapiesFrailty endpointsInflammatory biomarkers

Key terms

References

  1. Human senolytic pilot. Hickson et al., EBioMedicine, 2019
    Preliminary human dasatinib plus quercetin study in diabetic kidney disease.
  2. Senolytic clinical follow-up. Senolytic combination clinical literature, 2024
    Use for inflammation, tissue specificity, and clinical endpoint caution.

Cite this page

Future Human Atlas. “Senolytics and Senomorphics.” Last reviewed May 2026. https://futurehumanwiki.com/articles/senolytics

Suggest an edit